Cargando…

Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma

Diffuse large B cell lymphoma (DLBCL) is successfully treated with combination immuno-chemotherapy, but relapse with resistant disease occurs in ~ 40% of patients. However, little is known regarding relapsed/refractory DLBCL (rrDLBCL) genetics and alternative therapies. Based on findings from other...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benoit, Alexandre, Bou-Petit, Elisabeth, Chou, Hsiang, Lu, Melissa, Guilbert, Cynthia, Luo, Vincent Mingyi, Assouline, Sarit, Morin, Ryan D., Dmitrienko, Svetlana, Estrada-Tejedor, Roger, Johnson, Nathalie A., Mann, Koren K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764096/ https://www.ncbi.nlm.nih.gov/pubmed/35039569 http://dx.doi.org/10.1038/s41598-021-04736-0

Ejemplares similares

Arsenic Trioxide Overcomes Rapamycin-Induced Feedback Activation of AKT and ERK Signaling to Enhance the Anti-Tumor Effects in Breast Cancer
por: Guilbert, Cynthia, et al.
Publicado: (2013)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Arsenic 3 methyltransferase (AS3MT) automethylates on cysteine residues in vitro
por: Mersaoui, Sofiane Y., et al.
Publicado: (2022)

RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors
por: Furuse, Junji, et al.
Publicado: (2018)

A computationally engineered RAS rheostat reveals RAS/ERK signaling dynamics
por: Rose, John C., et al.
Publicado: (2016)

Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine
por: Assouline, Sarit, et al.
Publicado: (2023)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Bartlett, Nancy L., et al.
Publicado: (2023)

Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway
por: Pera, Benet, et al.
Publicado: (2018)

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Ras–ERK Signaling in Behavior: Old Questions and New Perspectives
por: Fasano, Stefania, et al.
Publicado: (2011)

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
por: Assouline, S E, et al.
Publicado: (2014)

Mulberry polyphenol extracts attenuated senescence through inhibition of Ras/ERK via promoting Ras degradation in VSMC
por: Chen, Ching-Pei, et al.
Publicado: (2022)

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
por: Matsue, Kosei, et al.
Publicado: (2015)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

The metastasis suppressor Nm23 as a modulator of Ras/ERK signaling
por: Takács-Vellai, Krisztina
Publicado: (2014)

The Ras-Erk-ETS-Signaling Pathway Is a Drug Target for Longevity
por: Slack, Cathy, et al.
Publicado: (2015)

Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs
por: Yue, Jingyin, et al.
Publicado: (2017)

Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of Ras
por: Frodyma, Danielle, et al.
Publicado: (2017)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
por: Gillies, Taryn E, et al.
Publicado: (2020)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially
por: Vantaggiato, Chiara, et al.
Publicado: (2006)

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
por: Budde, Lihua E., et al.
Publicado: (2022)

Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway
por: Reuveni, Hadas, et al.
Publicado: (2000)

CARD9 mediates Dectin-1–induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity
por: Jia, Xin-Ming, et al.
Publicado: (2014)

RasGRP1, but Not RasGRP3, Is Required for Efficient Thymic β-Selection and ERK Activation Downstream of CXCR4
por: Golec, Dominic P., et al.
Publicado: (2013)

Adaptor SKAP-55 Binds p21(ras) Activating Exchange Factor RasGRP1 and Negatively Regulates the p21(ras)-ERK Pathway in T-Cells
por: Schneider, Helga, et al.
Publicado: (2008)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Circadian clock-controlled diurnal oscillation of Ras/ERK signaling in mouse liver
por: TSUCHIYA, Yoshiki, et al.
Publicado: (2013)

Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors
por: Papale, Alessandro, et al.
Publicado: (2016)

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
por: Kochetkova, Elena Y., et al.
Publicado: (2017)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tp5led0i18oh46n19e7pd70chc